Artal Group Sa Has Trimmed Its Position in Fate Therapeutics INC (FATE) by $5.95 Million

Investors sentiment decreased to 1.08 in Q1 2019. Its down 0.52, from 1.6 in 2018Q4. It fall, as 11 investors sold FATE shares while 39 reduced holdings. 20 funds opened positions while 34 raised stakes. 55.48 million shares or 3.48% more from 53.61 million shares in 2018Q4 were reported. Cubist Systematic Strategies Limited Liability Corporation holds 2,862 shares. Grp Incorporated One Trading Limited Partnership invested in 0% or 4,364 shares. Vident Investment Advisory Limited Liability Corp invested in 0.09% or 96,315 shares. Sg Americas Lc holds 9,637 shares. Credit Suisse Ag holds 0% or 65,587 shares in its portfolio. Fmr Lc reported 7.05 million shares. 10 were reported by National Bank & Trust Of Montreal Can. Polar Capital Llp invested 0.01% in Fate Therapeutics, Inc. (NASDAQ:FATE). Jennison Associates Ltd Liability Corp holds 0.01% in Fate Therapeutics, Inc. (NASDAQ:FATE) or 487,044 shares. Renaissance Technologies Ltd Llc stated it has 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Partner Mgmt LP holds 0.16% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 7,872 shares. California Public Employees Retirement holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 54,816 shares. Tiaa Cref Invest Mgmt Limited Liability Corp invested in 0% or 99,950 shares. Doheny Asset Ca, California-based fund reported 27,450 shares. Bnp Paribas Arbitrage Sa has 12,602 shares for 0% of their portfolio.

Artal Group Sa decreased its stake in Fate Therapeutics Inc (FATE) by 16.28% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa sold 350,000 shares as the company’s stock rose 35.11% . The institutional investor held 1.80 million shares of the health care company at the end of 2019Q1, valued at $31.63 million, down from 2.15 million at the end of the previous reported quarter. Artal Group Sa who had been investing in Fate Therapeutics Inc for a number of months, seems to be less bullish one the $1.15 billion market cap company. The stock decreased 1.62% or $0.29 during the last trading session, reaching $17.59. About 443,930 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 152.00% since August 15, 2018 and is uptrending. It has outperformed by 152.00% the S&P500.

Artal Group Sa, which manages about $2.45B US Long portfolio, upped its stake in Nio Inc by 3.60 million shares to 4.60M shares, valued at $23.46 million in 2019Q1, according to the filing. It also increased its holding in Beigene Ltd by 400,000 shares in the quarter, for a total of 600,000 shares, and has risen its stake in Tricida Inc.

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Nasdaq.com which released: “Factors Likely to Decide PepsiCo’s (PEP) Fate in Q1 Earnings – Nasdaq” on April 10, 2019, also Nasdaq.com with their article: “Earnings Reaction History: FATE THERAPEUTC, 60.0% Follow-Through Indicator, 6.0% Sensitive – Nasdaq” published on March 05, 2019, Nasdaq.com published: “Kenya’s KCB Group confident of sealing NBK deal as H1 rises – Nasdaq” on August 15, 2019. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Nasdaq.com and their article: “U.S. to seek execution for Illinois man in gruesome slaying of Chinese student – Nasdaq” published on July 17, 2019 as well as Seekingalpha.com‘s news article titled: “Fate Therapeutics Q2 2019 Earnings Preview – Seeking Alpha” with publication date: August 05, 2019.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 4 analysts covering Fate Therapeutics (NASDAQ:FATE), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Fate Therapeutics has $2700 highest and $12 lowest target. $20.60’s average target is 17.11% above currents $17.59 stock price. Fate Therapeutics had 12 analyst reports since March 6, 2019 according to SRatingsIntel. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Hold” rating given on Wednesday, March 6 by H.C. Wainwright. On Wednesday, March 6 the stock rating was maintained by Wells Fargo with “Buy”.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.